MA30975B1 - Formulation parenterale d'anticorps anti-peptide abeta - Google Patents
Formulation parenterale d'anticorps anti-peptide abetaInfo
- Publication number
- MA30975B1 MA30975B1 MA31963A MA31963A MA30975B1 MA 30975 B1 MA30975 B1 MA 30975B1 MA 31963 A MA31963 A MA 31963A MA 31963 A MA31963 A MA 31963A MA 30975 B1 MA30975 B1 MA 30975B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibody
- parenteral formulation
- peptide antibody
- abeta
- mixture
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 2
- 230000002788 anti-peptide Effects 0.000 title 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE UNE FORMULATION PARENTÉRALE PHARMACEUTIQUE STABLE D'UN ANTICORPS, D'UNE MOLÉCULE D'ANTICORPS, D'UN MÉLANGE D'ANTICORPS ET/OU D'UN MÉLANGE DE MOLÉCULES D'ANTICORPS DIRIGÉS CONTRE LE PEPTIDE BÊTA-AMYLOÏDE (ABÊTA) ET UN PROCÉDÉ DE PRÉPARATION ASSOCIÉ. EN OUTRE, CETTE INVENTION CONCERNE ÉGALEMENT DES UTILISATIONS CORRESPONDANTES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06025590 | 2006-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA30975B1 true MA30975B1 (fr) | 2009-12-01 |
Family
ID=39190366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA31963A MA30975B1 (fr) | 2006-12-11 | 2009-06-08 | Formulation parenterale d'anticorps anti-peptide abeta |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20110070225A1 (fr) |
| EP (1) | EP2094729A1 (fr) |
| JP (1) | JP2010512356A (fr) |
| KR (1) | KR20090104017A (fr) |
| CN (1) | CN101553504A (fr) |
| AR (1) | AR064220A1 (fr) |
| AU (1) | AU2007331712A1 (fr) |
| BR (1) | BRPI0721097A2 (fr) |
| CA (1) | CA2671968A1 (fr) |
| CL (1) | CL2007003583A1 (fr) |
| CR (1) | CR10823A (fr) |
| EC (1) | ECSP099403A (fr) |
| IL (1) | IL198963A0 (fr) |
| MA (1) | MA30975B1 (fr) |
| MX (1) | MX2009006199A (fr) |
| NO (1) | NO20092586L (fr) |
| PE (1) | PE20081477A1 (fr) |
| RU (1) | RU2009126420A (fr) |
| TW (1) | TW200831133A (fr) |
| WO (1) | WO2008071394A1 (fr) |
| ZA (1) | ZA200904014B (fr) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| TW200530269A (en) | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| US9493569B2 (en) | 2005-03-31 | 2016-11-15 | Chugai Seiyaku Kabushiki Kaisha | Structural isomers of sc(Fv)2 |
| JP5085322B2 (ja) | 2005-06-10 | 2012-11-28 | 中外製薬株式会社 | ｓｃ（Ｆｖ）２を含有する医薬組成物 |
| EP1976877B2 (fr) | 2005-11-30 | 2016-10-05 | AbbVie Inc. | Anticorps monoclonaux contre la protein beta-amyloide et utilisation de ceux-ci |
| CA2628703C (fr) | 2005-11-30 | 2019-10-29 | Abbott Laboratories | Anticorps anti-globulomere a.beta., fractions de liaison aux antigenes de ceux-ci, hydridomes , acides nucleiques, vecteurs, cellules hotes correspondants, procedes de production des anticorps, compositions comprenant les anticorps, utilisations des anticorps et procedes d'utilisation de ces anticorps |
| JP5145241B2 (ja) * | 2005-12-12 | 2013-02-13 | エフ．ホフマン−ラ ロシュ アーゲー | 可変領域におけるグリコシル化を有するアミロイドβに対する抗体 |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| EP2124952A2 (fr) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Méthode de traitement d'amyloïdoses |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| SG10201505369QA (en) | 2007-10-05 | 2015-08-28 | Genentech Inc | Use of anti-amyloid beta antibody in ocular diseases |
| ES2759075T3 (es) | 2008-03-14 | 2020-05-07 | Biocon Ltd | Un anticuerpo monoclonal y un método del mismo |
| JP6146949B2 (ja) * | 2008-06-20 | 2017-06-21 | ノバルティス アーゲー | 凝集が低減された免疫グロブリン |
| MX2011002402A (es) * | 2008-09-19 | 2011-04-05 | Hoffmann La Roche | Formulacion de anticuerpo novedosa. |
| EP2346900A1 (fr) | 2008-10-29 | 2011-07-27 | Wyeth LLC | Procédés de purification de molécules de liaison d'antigène monodomaines |
| MX345226B (es) * | 2008-10-29 | 2017-01-20 | Ablynx Nv | Formulaciones de moleculas de union a antigeno de dominio sencillo. |
| MX2011005051A (es) * | 2008-11-17 | 2011-06-01 | Genentech Inc | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas. |
| EP2196476A1 (fr) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Formulation d'anticorps |
| WO2010069858A1 (fr) * | 2008-12-19 | 2010-06-24 | F. Hoffmann-La Roche Ag | Composition pharmaceutique |
| WO2010100179A2 (fr) * | 2009-03-05 | 2010-09-10 | Novartis Ag | Système de gel autoformé pour administration de médicament à libération lente |
| EP2501408B1 (fr) * | 2009-11-20 | 2020-05-27 | Biocon Limited | Formulations d'anticorps |
| WO2011080209A2 (fr) * | 2009-12-29 | 2011-07-07 | F. Hoffmann-La Roche Ag | Nouvelle formation d'anticorps |
| AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
| US9795674B2 (en) | 2010-02-26 | 2017-10-24 | Novo Nordisk A/S | Stable antibody containing compositions |
| SI2542257T1 (en) | 2010-03-01 | 2018-01-31 | Bayer Healthcare Llc | Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI) |
| MX2012009460A (es) | 2010-03-03 | 2012-09-12 | Boehringer Ingelheim Int | Polipeptidos biparatopicos de union abeta. |
| US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| CA2800188A1 (fr) | 2010-05-28 | 2011-12-01 | Novo Nordisk A/S | Compositions stables multi-doses comprenant un anticorps et un agent conservateur |
| KR101713365B1 (ko) | 2010-07-30 | 2017-03-08 | 에이씨 이뮨 에스.에이. | 안전하고 기능적인 인간화 항 베타-아밀로이드 항체 |
| MX358739B (es) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Proteinas de union a amiloide beta. |
| WO2012028683A1 (fr) * | 2010-09-02 | 2012-03-08 | Novartis Ag | Système de gel d'anticorps pour administration de médicament prolongée |
| WO2012151199A1 (fr) | 2011-05-02 | 2012-11-08 | Immunomedics, Inc. | Concentration d'ultrafiltration d'anticorps à allotype sélectionné pour une administration de petit volume |
| AU2012250872B2 (en) * | 2011-05-02 | 2017-07-13 | Millennium Pharmaceuticals, Inc. | Formulation for anti-alpha4beta7 antibody |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| HK1198689A1 (en) * | 2011-10-25 | 2015-05-29 | Prothena Biosciences Limited | Antibody formulations and methods |
| WO2013131866A1 (fr) * | 2012-03-08 | 2013-09-12 | F. Hoffmann-La Roche Ag | Formulation d'anticorps anti-peptide abêta |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| EP2830658B1 (fr) * | 2012-03-26 | 2018-10-10 | Sanofi | Formulations stables d'agent de liaison à igg4 |
| US20130281355A1 (en) | 2012-04-24 | 2013-10-24 | Genentech, Inc. | Cell culture compositions and methods for polypeptide production |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| EP2968538A1 (fr) * | 2013-03-15 | 2016-01-20 | Bayer HealthCare LLC | Formulations d'anticorps anti-récepteurs de prolactine |
| EP3024485B1 (fr) | 2013-07-23 | 2020-11-18 | Biocon Limited | Utilisation d'un partenaire de liaison de cd6 et procédé associé |
| US20160114000A1 (en) | 2014-10-24 | 2016-04-28 | Merck Sharp & Dohme Corp. | Co-agonists of the glucagon and glp-1 receptors |
| EP3207936B1 (fr) * | 2014-11-18 | 2021-04-21 | Shionogi & Co., Ltd. | Composition de peptide stable |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| CN104946616A (zh) * | 2015-05-12 | 2015-09-30 | 骏实生物科技(上海)有限公司 | 一种用于体外诊断试剂的通用固体稳定剂及其使用方法 |
| AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
| IL302486A (en) | 2015-06-24 | 2023-06-01 | Hoffmann La Roche | Antibodies against the transnephrine receptor with adapted affinity |
| RS64263B1 (sr) * | 2015-08-19 | 2023-07-31 | Astrazeneca Ab | Stabilna anti-ifnar1 formulacija |
| EP3352790A1 (fr) * | 2015-09-22 | 2018-08-01 | Pfizer Inc | Procédé de préparation d'une formulation de protéine thérapeutique et formulation d'anticorps produite par un tel procédé |
| KR20250007038A (ko) | 2015-10-02 | 2025-01-13 | 에프. 호프만-라 로슈 아게 | 이중특이성 항-인간 cd20/인간 트랜스페린 수용체 항체 및 사용 방법 |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| CN106620691B (zh) * | 2015-11-04 | 2020-08-21 | 信达生物制药(苏州)有限公司 | 一种重组全人源抗ctla-4单克隆抗体制剂及其应用 |
| SG11201804961UA (en) | 2015-12-30 | 2018-07-30 | Genentech Inc | Formulations with reduced degradation of polysorbate |
| CN106199007B (zh) * | 2016-08-03 | 2017-04-05 | 烟台普罗吉生物科技发展有限公司 | 蛋白保护剂 |
| JP7071974B2 (ja) | 2016-10-21 | 2022-05-19 | バイオコン・リミテッド | モノクローナル抗体および狼瘡の処置のための使用の方法 |
| CN106913869B (zh) * | 2017-03-17 | 2020-07-28 | 信达生物制药(苏州)有限公司 | 一种抗ctla-4单克隆抗体制剂及其应用 |
| CN110352201A (zh) | 2017-04-03 | 2019-10-18 | 免疫医疗公司 | 用于癌症疗法的抗体药物缀合物的皮下施用 |
| EP3672631B9 (fr) * | 2017-08-22 | 2023-06-28 | Biogen MA Inc. | Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes |
| CN108373494A (zh) * | 2018-02-27 | 2018-08-07 | 武汉伊艾博科技有限公司 | 一种防止重组蛋白质降解的保护技术 |
| CR20210435A (es) | 2019-02-18 | 2021-09-20 | Lilly Co Eli | Formulación de anticuerpos terapéuticos |
| CN112618482A (zh) * | 2019-09-24 | 2021-04-09 | 江苏恒瑞医药股份有限公司 | 新型蛋白制剂 |
| CN112741804A (zh) * | 2019-10-31 | 2021-05-04 | 上海君实生物医药科技股份有限公司 | 含有抗pd-l1抗体的稳定制剂 |
| CN113116812A (zh) * | 2019-12-30 | 2021-07-16 | 百奥泰生物制药股份有限公司 | 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用 |
| WO2022072255A1 (fr) * | 2020-09-30 | 2022-04-07 | Merck Sharp & Dohme Corp. | Protéines de liaison et fragments de liaison à l'antigène de celles-ci se liant à abêta |
| US20240417451A1 (en) | 2023-05-31 | 2024-12-19 | Hoffmann-La Roche Inc. | Therapeutic Use of Bispecific Anti-Abeta/TfR Antibodies |
| CN117088974B (zh) * | 2023-08-14 | 2024-02-13 | 武汉健昊生物科技有限公司 | 一种抗体保存液 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| DE60235013D1 (de) * | 2001-07-25 | 2010-02-25 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| EP3178492A1 (fr) * | 2003-04-04 | 2017-06-14 | Genentech, Inc. | Formules de protéine et d'anticorps à concentration élevée |
| GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| DOP2006000022A (es) * | 2005-01-28 | 2006-08-15 | Wyeth Corp | Formulaciones líquidas estabilizadas de polipetidos |
| JP5145241B2 (ja) * | 2005-12-12 | 2013-02-13 | エフ．ホフマン−ラ ロシュ アーゲー | 可変領域におけるグリコシル化を有するアミロイドβに対する抗体 |
| EP1998806A1 (fr) * | 2006-03-28 | 2008-12-10 | F. Hoffmann-Roche AG | Formulation d'anticorps monoclonal humain anti-igf-1r |
-
2007
- 2007-12-11 AR ARP070105523A patent/AR064220A1/es unknown
- 2007-12-11 EP EP07856573A patent/EP2094729A1/fr not_active Withdrawn
- 2007-12-11 BR BRPI0721097-3A patent/BRPI0721097A2/pt not_active IP Right Cessation
- 2007-12-11 AU AU2007331712A patent/AU2007331712A1/en not_active Abandoned
- 2007-12-11 JP JP2009540650A patent/JP2010512356A/ja not_active Withdrawn
- 2007-12-11 CN CNA2007800455861A patent/CN101553504A/zh active Pending
- 2007-12-11 KR KR1020097013954A patent/KR20090104017A/ko not_active Withdrawn
- 2007-12-11 PE PE2007001764A patent/PE20081477A1/es not_active Application Discontinuation
- 2007-12-11 RU RU2009126420/10A patent/RU2009126420A/ru not_active Application Discontinuation
- 2007-12-11 CL CL200703583A patent/CL2007003583A1/es unknown
- 2007-12-11 TW TW096147285A patent/TW200831133A/zh unknown
- 2007-12-11 WO PCT/EP2007/010825 patent/WO2008071394A1/fr not_active Ceased
- 2007-12-11 US US12/448,190 patent/US20110070225A1/en not_active Abandoned
- 2007-12-11 MX MX2009006199A patent/MX2009006199A/es not_active Application Discontinuation
- 2007-12-11 CA CA002671968A patent/CA2671968A1/fr not_active Abandoned
-
2009
- 2009-05-21 CR CR10823A patent/CR10823A/es not_active Application Discontinuation
- 2009-05-26 IL IL198963A patent/IL198963A0/en unknown
- 2009-06-08 MA MA31963A patent/MA30975B1/fr unknown
- 2009-06-09 ZA ZA200904014A patent/ZA200904014B/xx unknown
- 2009-06-11 EC EC2009009403A patent/ECSP099403A/es unknown
- 2009-07-07 NO NO20092586A patent/NO20092586L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL198963A0 (en) | 2011-08-01 |
| MX2009006199A (es) | 2009-06-22 |
| WO2008071394A1 (fr) | 2008-06-19 |
| NO20092586L (no) | 2009-07-17 |
| PE20081477A1 (es) | 2008-10-18 |
| RU2009126420A (ru) | 2011-01-20 |
| US20110070225A1 (en) | 2011-03-24 |
| EP2094729A1 (fr) | 2009-09-02 |
| TW200831133A (en) | 2008-08-01 |
| ECSP099403A (es) | 2009-07-31 |
| CR10823A (es) | 2009-08-12 |
| AR064220A1 (es) | 2009-03-18 |
| AU2007331712A1 (en) | 2008-06-19 |
| CA2671968A1 (fr) | 2008-06-19 |
| CN101553504A (zh) | 2009-10-07 |
| BRPI0721097A2 (pt) | 2014-07-01 |
| ZA200904014B (en) | 2010-04-28 |
| KR20090104017A (ko) | 2009-10-05 |
| CL2007003583A1 (es) | 2008-07-18 |
| AU2007331712A2 (en) | 2009-07-30 |
| JP2010512356A (ja) | 2010-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA30975B1 (fr) | Formulation parenterale d'anticorps anti-peptide abeta | |
| El Magraoui et al. | The RING‐type ubiquitin ligases Pex2p, Pex10p and Pex12p form a heteromeric complex that displays enhanced activity in an ubiquitin conjugating enzyme‐selective manner | |
| Mainardi et al. | Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the β-lactam imipenem | |
| Desai et al. | Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin | |
| Hosea et al. | Elucidation of distinct ligand binding sites for cytochrome P450 3A4 | |
| Porter et al. | Reciprocal regulation of Hck activity by phosphorylation of Tyr527 and Tyr416: effect of introducing a high affinity intramolecular SH2 ligand | |
| Grou et al. | Members of the E2D (UbcH5) family mediate the ubiquitination of the conserved cysteine of Pex5p, the peroxisomal import receptor | |
| Cooper et al. | Specificity of the BRISC deubiquitinating enzyme is not due to selective binding to Lys63-linked polyubiquitin | |
| Cantor et al. | The human asparaginase-like protein 1 hASRGL1 is an Ntn hydrolase with β-aspartyl peptidase activity | |
| Dickerhof et al. | Bacitracin inhibits the reductive activity of protein disulfide isomerase by disulfide bond formation with free cysteines in the substrate‐binding domain | |
| MA30345B1 (fr) | Formulation d'anticorps monoclonal humain anti-igf-1r | |
| Wilmouth et al. | Mechanistic insights into the inhibition of serine proteases by monocyclic lactams | |
| EA200100589A1 (ru) | Азабициклоалканы как модуляторы ccr5 | |
| MY138289A (en) | Pharmaceutical compositions | |
| Ettari et al. | Novel peptidomimetics containing a vinyl ester moiety as highly potent and selective falcipain-2 inhibitors | |
| EA200100588A1 (ru) | Пиперидины как модуляторы ccr5 | |
| MA32099B1 (fr) | Composition comprenant un anticorps se liant au domaine ii de her2 et variantes acides de celle-ci | |
| MA30689B1 (fr) | Derives de leptomycine | |
| UA84432C2 (ru) | Очищенные пептиды и соединения, которые их содержат | |
| Cellini et al. | Molecular insight into the synergism between the minor allele of human liver peroxisomal alanine: glyoxylate aminotransferase and the F152I mutation | |
| MA33761B1 (fr) | Dispersion solide de rifaximine | |
| Yu et al. | Characterization of dextromethorphan O-and N-demethylation catalyzed by highly purified recombinant human CYP2D6 | |
| WO2001059149A3 (fr) | Biocapteurs peptidiques destines a la protease du charbon bacteridien | |
| MXPA04000210A (es) | Conjugados quelantes mejorados. | |
| WO2003107009A3 (fr) | Methodes d'amelioration d'une liaison caracteristique d'une molecule |